Monday, March 21, 2022 5:06:41 PM
New Alzheimer's Vulnerability Tests
Very good question, which a few years ago would have been more difficult to answer. But in the last year, several new diagnostic tests have been formulated to accurately detect solid vulnerabilities for the eventual onset of Alzheimer's. All of these will need their own clinical validation, but that shouldn't be difficult. Merely take a blood, genomic or other sample and see if the new Alzheimer's vulnerability test is successful.
When a test is confirmed, a new blarcamesine trial will be in order. Get a thousand older people enrolled in the trial, all of whom have been diagnosed with a valid Alzheimer's vulnerability. Give half a placebo starch pill (with the name "Anavex" imprinted on it) and the other half get a visually identical pill containing blarcamesine. In two or three years, compare the frequencies of Alzheimer's in the two cohorts. The people in the placebo arm will have a certain frequency. Those in the blarcamesine arm will have fewer or no cases appearing. Matter settled. Health insurance companies eager to get all of their paying clients older than 50 on blarcamesine. Everybody (well, except for nursing homes and Alzheimer's care facilities and doctors) wins.
I am puzzled at how (without very accurate diagnoses and testing) they would prove that an Alzheimer’s patient has been prevented from getting Alzheimer’s?
Very good question, which a few years ago would have been more difficult to answer. But in the last year, several new diagnostic tests have been formulated to accurately detect solid vulnerabilities for the eventual onset of Alzheimer's. All of these will need their own clinical validation, but that shouldn't be difficult. Merely take a blood, genomic or other sample and see if the new Alzheimer's vulnerability test is successful.
When a test is confirmed, a new blarcamesine trial will be in order. Get a thousand older people enrolled in the trial, all of whom have been diagnosed with a valid Alzheimer's vulnerability. Give half a placebo starch pill (with the name "Anavex" imprinted on it) and the other half get a visually identical pill containing blarcamesine. In two or three years, compare the frequencies of Alzheimer's in the two cohorts. The people in the placebo arm will have a certain frequency. Those in the blarcamesine arm will have fewer or no cases appearing. Matter settled. Health insurance companies eager to get all of their paying clients older than 50 on blarcamesine. Everybody (well, except for nursing homes and Alzheimer's care facilities and doctors) wins.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
